Unknown NA INTERVENTIONAL 1-arm NCT02333513

A Study to Evaluate the Safety and Effectiveness of PCV Chemotherapy in Patients With Recurrent High-grade Glioma With IDH1/2 Mutation

Sponsor: Beijing Tiantan Hospital

Interventions Lomustine/Vincristine/Procarbazine

Updated 6 times since 2017 Last updated: Apr 8, 2015 Started: Feb 28, 2015 Primary completion: Dec 31, 2017 Completion: Dec 31, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02333513, this NA trial focuses on Recurrent High-grade Glioma and remains ongoing. Sponsored by Beijing Tiantan Hospital, it has been updated 6 times since 2015, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Unknown NA
Jul 2024 — Sep 2024 [monthly]

Unknown NA

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status NA
Jun 2018 — Jan 2021 [monthly]

Unknown Status NA
Feb 2018 — Jun 2018 [monthly]

Unknown Status NA

Status: Not Yet Recruiting → Unknown Status

▶ Show 1 earlier version

Jan 2017 — Feb 2018 [monthly]

Not Yet Recruiting NA

First recorded

Feb 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Beijing Tiantan Hospital
Hebei Yanda Hospital

Data source: Hebei Yanda Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China
• Sanhe, China